title: [Efficacy and safety of a reduced-dose of stavudine in HIV-infected patients under immunological and virological stable conditions].
abstract: OBJECTIVE
  Stavudine (d4T) has shown a favourable short and long-term tolerability profile. Nevertheless, its usage is currently decreasing due to some safety concerns. We aimed to evaluate the efficacy and safety of d4T low-dose-based regimens.
  
  
  METHODS
  This was a multicenter and retrospective review chart of patients receiving standard doses of d4T for > or = 6 months (weight > 60 kg: 40 mg/12 h; weight < 60 kg: 30 mg/12 h) and having undetectable viral load for at least 3 months before the d4T dose reduction (weight > 60 kg: 30 mg/12 h; weight < 60 kg: 20 mg/12 h). Immunological and viral parametres, lipid profile and side effects were determined.
  
  
  RESULTS
  A total of 982 patients were included. The main reason for reducing the dose was prevention of toxicity (76%). After 6 months of follow-up, 97% and 84% patients had less than 400 and 50 cp/ml, respectively, and the CD4 cell count increased by 38 cel/ml. Lipids, lipodystrophy and peripheral polineuropathy improved but there was no statistical significance.
  
  
  CONCLUSIONS
  A d4T dose reduction in an immuno-virologically stable population does not affect treatment efficacy. Longer follow-ups are required to confirm improvements in the safety profile.
authors.affiliation: Unitat de Malalties Infeccioses-VIH, Hospital General de Granollers, Granollers, Barcelona, España. epedrol@fhag.es
authors.forename: Enric
authors.initials: E
authors.lastname: Pedrol
authors.forename: Teodoro
authors.initials: T
authors.lastname: Martín
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: del Pozo
authors.forename: Juan
authors.initials: J
authors.lastname: Flores
authors.forename: José
authors.initials: J
authors.lastname: Sanz
authors.forename: José A
authors.initials: JA
authors.lastname: Cartón
authors.forename: Juan-José
authors.initials: JJ
authors.lastname: Jusdado
authors.forename: Piedad
authors.initials: P
authors.lastname: Arazo
authors.forename: Esteve
authors.initials: E
authors.lastname: Ribera
authors.forename: Elisabet
authors.initials: E
authors.lastname: Deig
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage*; D018119:Stavudine / Q000008:administration & dosage*; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D018119:Stavudine